ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 768.7 EUR | +0.47% |
|
+3.34% | +45.18% |
| 06/06 | US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug | RE |
| 06/06 | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
| Sales 2024 * | 42.98B 39.44B 3,587B | Sales 2025 * | 52.62B 48.29B 4,392B | Capitalization | 754B 692B 62,914B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 10.95B 996B | Net income 2025 * | 16.55B 15.19B 1,381B | EV / Sales 2024 * | 18 x |
| Net Debt 2024 * | 18.07B 16.58B 1,508B | Net Debt 2025 * | 15B 13.76B 1,252B | EV / Sales 2025 * | 14.6 x |
| P/E ratio 2024 * |
62.6
x | P/E ratio 2025 * |
45.1
x | Employees | - |
| Yield 2024 * |
0.62% | Yield 2025 * |
0.72% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 week | +2.47% | ||
| Current month | +1.81% | ||
| 1 month | +8.13% | ||
| 3 months | +7.21% | ||
| 6 months | +40.15% | ||
| Current year | +45.86% |
1 week
747.10
778.30
1 month
694.40778.30
3 years
166.30778.30
5 years
94.06778.30
10 years
43.49778.30
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/23/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
| Date | Price | Change |
|---|---|---|
| 06/24/06 | 768.7 | +0.47% |
| 05/24/05 | 765.1 | 0.00% |
| 04/24/04 | 765.1 | +0.29% |
| 03/24/03 | 762.9 | +1.05% |
| 31/24/31 | 755 | +0.64% |
Real-time BOERSE MUENCHEN, June 07, 2024 at 01:29 am IST
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
837.3
USD
Average target price
852.5
USD
Spread / Average Target
+1.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.42% | 605B | |
| -6.58% | 351B | |
| +19.72% | 328B | |
| +8.78% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.03% | 167B | |
| +6.13% | 165B | |
| +1.39% | 123B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock
